RARE News and Press, Ultragenyx Pharmaceutical Inc. From 06/01/22

NOVATO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D....

Regeneron Pharmaceuticals (NASDAQ:REGN) said a phase 3 trial of Evkeeza (evinacumab) met its main goal in children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). HoFH is a rare inherited condition and is a type of of familial hypercholesterolemia — a disor...

Durable and clinically meaningful responses sustained for more than three years post-treatment in study of DTX401 for GSDIa and four or more years in study of DTX301 for OTC NOVATO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmace...

ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA Interim data featured in encore oral presentation at American Society of Gene & Cell Therapy (ASGCT) today NOVATO, Calif. and NEW YORK and CLEVELAND, May 17, 2022 (GLOBE N...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

NOVATO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that clinical, preclinical and manufacturing data ...

Cowen analyst Yaron Werber lowered Ultragenyx Pharmaceutical's (NASDAQ:RARE) price target to $99 from $124 after Q1 results. The Outperform rating on the shares were maintained. RARE's Q1 GAAP EPS of -$2.19 misses by $0.41, revenue of $79.9M misses by $4.35M. For further details s...

Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2022 Earnings Conference Call May 05, 2022, 17:00 ET Company Participants Joshua Higa - Director, IR & Corporate Communications Emil Kakkis - President, CEO & Director Erik Harris - EVP & Chief Commercial Officer Mardi Dier - EVP & CFO...

Ultragenyx Pharmaceutical press release (NASDAQ:RARE): Q1 GAAP EPS of -$2.19 misses by $0.41. Revenue of $79.9M (-19.6% Y/Y) misses by $4.35M. Shares -6.46%. For further details see: Ultragenyx Pharmaceutical GAAP EPS of -$2.19 misses by $0.41, revenue of $79.9M misses by $4.35M